Search the Newsreel

Forte Biosciences Agrees to Be Acquired by Argenx in $2.2 Billion Deal

Forte Biosciences (FBRX) shares surged early Monday after the company agreed to be acquired by Belgi PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already …

Forte Biosciences shares jump after $2.2 billion takeover agreement with argenx

Stock chart with green arrow moving up ©Adobe Stock Images Forte Biosciences (NASDAQ:FBRX) shares climbed 39.2% in pre-market trading after argenx (NASDAQ:ARGX) announced a definitive agreement to acquire the clinical-stage biotechnology company in an all-cash transaction valued at approximately $2.2 billion. Under the terms …

Argenx agrees $2.2 billion acquisition of Forte Biosciences to strengthen autoimmune drug pipeline

Medical researcher in gloves using a tablet ©Adobe Stock Images Argenx NV ADR (NASDAQ:ARGX) has agreed to acquire Forte Biosciences Inc (NASDAQ:FBRX) in a transaction valued at approximately $2.2 billion, expanding its portfolio of autoimmune disease treatments as it looks to build new growth …

argenx strikes $2.2B deal for Forte Biosciences

[Colorful collage. Hands holding orange and blue puzzle pieces representing corporate merger and innovation] * argenx SE (ARGX [https://seekingalpha.com/symbol/ARGX]) to acquire [https://seekingalpha.com/pr/20595280-argenx-to-acquire-forte-biosciences-inc-adding-first-in-class-anti-cd122-antibody-fb102-to] Forte Biosciences (FBRX [https://seekingalpha.com/symbol/FBRX]) for $77 per share in cash, valuing the transaction at ~$2.2B. * The acquisition will add Forte’s lead …

argenx To Acquire Forte Biosciences: What Investors Should Know (NASDAQ:ARGX)

Argenx To Acquire Forte For Approx. $2.2 Bln To Expand Immunology Pipeline; Forte Shares Soar

(RTTNews) - Argenx (ARGX), an immunology company, and Forte Biosciences, Inc. (FBRX),a clinical-stage biopharmaceutical company on Monday announced that they have entered into a definitive agreement under which Argenx will acquire Forte Biosciences for $77 per share in cash, representing a total equity value …

argenx Acquires Forte Biosciences for $2.2 Billion

argenx has agreed to acquire Forte Biosciences for approximately $2.2 billion, paying $77 per share in cash. This acquisition is driven by Forte's FB102, which has shown positive Phase 1b results in vitiligo and celiac disease, thereby strengthening argenx's immunology portfolio and aligning with …

argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class Anti-CD122 Antibody, FB102, to Its Immunology Pipeline

Transaction builds on argenx's prior strategic investment in Forte Biosciences and reflects a disciplined approach to accessing novel biology that can fuel long-term growth FB102 Phase 1b studies in vitiligo and celiac disease validate CD122 biology and pipeline-in-a-product potential to address diseases with high …

Argenx stock trades steady as efgartigimod growth offsets higher R&D spending

Argenx's stock reflects a balance between the rapid revenue growth of its antibody fragment therapy, efgartigimod, and significant R&D investments. Recent quarterly reports show total revenue reached $388 million, driven by efgartigimod's launch, while R&D spending increased to $210 million. Despite increased costs, the …

Argenx stock holds as investors await the next update

Argenx (NL0010832176), a Netherlands-based biotech group, continues to be a closely watched stock, with its performance primarily driven by quarterly execution, pipeline milestones, and share-price positioning. Investors are focused on the company's antibody platform, rare-disease franchise, and the impact of treatment adoption and pipeline …

Argenx stock trades steady as Uplizna growth and Vyvgart expansion shape outlook

Argenx stock reflects a company transitioning from a development stage to a commercial autoimmune specialist, driven by robust double-digit revenue growth from Vyvgart and Uplizna, alongside substantial ongoing investments in R&D. The company's recent quarterly results highlight expanding patient access and successful commercialization of …

ARGX|argenx SE|Price:925.050|Chg%:+73.330

argenx SE (ARGX) is a biopharmaceutical company focused on developing antibody therapeutics for severe autoimmune diseases. Its fundamentals are stable with good growth potential, though its valuation is considered fairly valued. Analysts have rated ARGX as "Buy" with a target price of $1057.22, indicating …

argenex (NASDAQ:ARGX) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says

Oppenheimer Issues Positive Forecast for argenex (NASDAQ:ARGX) Stock Price

Argenx (ENXTBR:ARGX) Stock Faces Margin Compression As 32.3% Profitability Tests Bullish Narrative

Guggenheim Issues Positive Forecast for argenex (NASDAQ:ARGX) Stock Price

argenx SE (ARGX) Stock Price, News, Quote & History

This article provides comprehensive financial data for argenx SE (ARGX), a commercial-stage biopharma company, including its stock price, historical performance, key financial metrics, and analyst ratings. It highlights the company's focus on developing therapies for autoimmune diseases and lists its main products and pipeline …

argenx SE (ARGNF) Q2 2026 Earnings Call Highlights: Robust Growth and Strategic Advances

This article first appeared on GuruFocus. Product Net Sales: $1.5 billion for Q2 2026, 60% year-over-year growth, 17% quarter-over-quarter growth. US Product Net Sales: $1.3 billion, 15% quarter-over-quarter growth. Japan Product Net Sales: $102 million, 55% quarter-over-quarter growth, including a $25 million one-off benefit. …

Argenx stock steadies as investors weigh Vyvgart growth and profitability path

Argenx stock reflects a balance between strong Vyvgart revenue growth and ongoing operating losses. The company reported a significant increase in Vyvgart sales, reaching approximately $400 million in the latest quarter, while still incurring a net loss due to heavy investment in R&D and …

argenx (NASDAQ: ARGX) grows Q2 sales to $1.5B, profit $838M

argenx SE reported strong half-year 2026 results, driven by VYVGART sales, with product net sales reaching $1.5 billion in Q2 and $2.8 billion for the first six months. The company's profit doubled to $838 million for the half-year, and it ended the period with …

argenx Reports Half Year 2026 Financial Results and Provides Second Quarter Business Update

argenx SE reported strong second-quarter 2026 financial results with $1.5 billion in global product net sales, a 60% year-over-year increase, driven by the expanded label launch of VYVGART and VYVGART Hytrulo for all gMG serotypes. The company is on track for several key registrational …

argenx VYVGART Sales Rise 60% as Pipeline Readouts Approach

argenex (NASDAQ:ARGX) Trading Up 6.3% on Strong Earnings

argenx SE GAAP EPS of $7.32 beats by $1.12, revenue of $1.52B beats by $90M

* argenx SE press release [https://seekingalpha.com/pr/20592469-argenx-reports-half-year-2026-financial-results-and-provides-second-quarter-business-update] (ARGX [https://seekingalpha.com/symbol/ARGX]): Q2 GAAP EPS of $7.32 beats by $1.12. * Revenue of $1.52B (+60.0% Y/Y) beats by $90M. * Cash flow from operating activities for the six months ended June 30, 2026 was $0.7 billion compared to …

Argenx Se (ARGX) Receives a Buy from Guggenheim

Guggenheim reiterated a Buy rating for Argenx Se (ARGX) with a price target of $1,135.00, according to an analyst report. This recommendation is supported by analyst Yatin Suneja's strong track record and a general "Strong Buy" consensus for ARGX with an average price target …

Argenx stock holds steady after 2025 revenue growth

Argenx stock has shown stability following strong revenue growth in 2025, with total revenue reaching EUR 2.13 billion, a 93% increase from 2024. The company also turned profitable, reporting diluted earnings per share of EUR 1.74 compared to a loss in the previous year, …

Argenx stock trades steady as investors weigh recent Vyvgart growth and cash position

Argenx stock shows stability as investors evaluate the strong revenue growth of its autoimmune therapy, Vyvgart, and the company's substantial cash reserves. The article details Vyvgart's impressive revenue increase in FY 2023, significant cash position, and ongoing clinical pipeline developments aimed at expanding the …

Argenx stock trades steady as Q1 2026 revenue grows and new Vyvgart data supports pipeline

Argenx stock is trading steadily following a mix of rising Q1 2026 revenue and continued clinical progress with its drug Vyvgart. The company reported a significant increase in total revenue for Q1 2026, primarily driven by Vyvgart sales, while also maintaining high investment in …

Argenx stock trades steady as Vyvgart growth underpins revenue outlook

Argenx stock performance is characterized by the strong revenue growth of its drug Vyvgart, which underpins the company's financial outlook despite widening operating losses due to significant R&D investments. The company is transitioning from a development-stage biotech to a commercial-stage entity, with Vyvgart sales …

Argenx stock trades near recent highs as Vyvgart growth drives revenue

Argenx stock is trading near recent highs, supported by strong revenue growth driven primarily by its autoimmune therapy Vyvgart. While the company is experiencing significant top-line expansion, operating expenses are also rising due to global launches and clinical development, leading to wider operating losses. …

Argenx stock trades steady as investors weigh recent revenue growth and clinical pipeline progress

Argenx stock is holding steady as investors consider the company's strong revenue growth, driven by its lead autoimmune therapy, and its ongoing investments in a deep immunology pipeline. The company's financial health, including substantial cash reserves, supports its capital-intensive R&D efforts. Future growth is …

Argenx stock trades steady as latest earnings detail growing immunology revenue

Argenx stock is holding steady, driven by strong growth in immunology revenue, particularly from its FcRn antibody franchise. The company reported double-digit top-line growth in Q1 2025 and 70% revenue increase in fiscal 2024, despite continued net losses due to heavy R&D investment. With …

Argenx stock trades steady as Vyvgart growth and cash position shape outlook

Argenx stock performance is influenced by the rapid revenue growth of its drug Vyvgart, primarily in autoimmune neuromuscular indications, and its substantial cash reserves funding an extensive clinical pipeline. The company reported a more than threefold increase in total revenue in 2023, reaching approximately …

Argenx stock trades near record levels as oncology deal follows strong Q1 growth

Argenx stock is trading near record levels after reporting strong growth in Q1 2026, with total revenue up 33% to $532 million and net income doubling. The company's financial health is also bolstered by a 2024 oncology collaboration and its flagship Vyvgart antibody therapy, …

Argenx stock trades steady as Vyvgart growth supports long term revenue outlook

Argenx stock is holding steady, driven by the strong revenue growth of its Vyvgart therapy for autoimmune diseases, which has seen double-digit and even triple-digit increases. Despite rapid top-line growth, the company continues to report operating losses due to significant investments in its autoimmune …

argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026

argenx announced that it will host a conference call and audio webcast on Thursday, July 23, 2026, at 2:30 p.m. CET (8:30 a.m. ET) to discuss its half-year 2026 financial results and provide a second-quarter business update. The webcast will be accessible on the …